| Revenue guidance | 15.0% → 20.0% Raised by 5.0 percentage points |
|---|---|
| Management target | Revenue 20.0% FY27 |
| Revenue growth | Revenue +24% YoY, +9% QoQ; broad-based across geographies, not one-time. |
|---|---|
| Margins | EBITDA margin 20.4%, +100bps YoY, +70bps QoQ; productivity-driven. |
| Order book | ARV order book described as strong; no figures given. |
| Demand visibility | India growth accelerating; Zoventa recovery expected stronger in H2. |
| Management confidence | Confident but repetitive; deflected on FY28 and product-level details. |
Growth
Revenue +24% YoY and +9% QoQ. India +12% (organic 10%, up from 6%); international +34.5%. EBITDA margin 20.4%, up 100bps.
Outlook
FY27 revenue growth now above 20%, up from mid-teens. EBITDA margin gain near top of 75–100bps. Net cash targeted by FY28.
Risks
Net debt ₹1,317 Cr after ₹551 Cr acquisition payouts. Input and freight costs rising; FY28 guidance withheld.
Last quarter's promises, checked
Delivered
- FY27 rev growth low-to-mid-teens → Q2 +24% YoY, FY27 guide raised to >20% (= BEAT)
- EBITDA margin +70–100bps → +100bps YoY to 20.4% (= BEAT)
- Net debt ~₹1,450 Cr by Q2-end → ₹1,317 Cr (= BEAT)
Partly delivered
- India in line with IPM in Q2, faster in H2 → India +12%, organic 10%; IPM not disclosed (= PARTIAL)
Missed
- Semaglutide Canada launch in Q2 via Reddy's → supply timing still pending (= MISS)
Earnings Call Transcript filed with BSE, NSE: EMCURE. Summary written with AI assistance from the document.
Emcure Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,174.20
- Market cap
- ₹41,247 Cr
- Revenue (annual)
- ₹9,204 Cr
- Net profit (annual)
- ₹924.4 Cr
- P/E (TTM)
- 37.7×Sector 41.3×
- Promoter holding
- 77.82%-0.01% QoQ
- FII holding
- 4.94%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Emcure Pharmaceuticals Ltd
All →Emcure Pharmaceuticals Investor Presentation: Key Takeaways
Q2FY27 revenue INR 28,205 Mn (+24.3% YoY), EBITDA INR 5,748 Mn (20.4% margin, +103 bps), PAT INR 3,251 Mn (+29.3%). International-led growth; net debt rose on acquisition payments.
Emcure Pharmaceuticals Q2 FY27 Results: Net Profit ₹325.1 Cr, Up 29.3% YoY
Emcure Pharmaceuticals Ltd reported revenue from operations of ₹2,820 Cr (+24.3% YoY) and net profit of ₹325.1 Cr (+29.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹325.1 Cr · +29.3% YoY
Emcure Pharmaceuticals Other Announcement
Emcure Pharmaceuticals submitted its quarterly shareholding pattern for the period ended September 30, 2026. This filing is a routine regulatory compliance disclosure under SEBI.
Emcure Pharmaceuticals Board Meeting Date
Emcure Pharmaceuticals will hold a board meeting on November 03, 2026, to consider and approve the company's standalone and consolidated financial results for the quarter.
Emcure Pharmaceuticals Acquisition
Emcure Pharmaceuticals approved the merger of its wholly-owned subsidiaries, Zuventus Healthcare and Emcutix Biopharmaceuticals, into itself. The internal restructuring involves no cash consideration or share issuance.
Emcure Pharmaceuticals Legal & Regulatory
Emcure Pharmaceuticals received Income-tax Department orders imposing aggregate penalties of Rs. 57.74 Crore for assessment years 2015-16 to 2021-22. The company is evaluating legal remedies.
- Value
- ₹57.74 Cr